Focus on improving our planet.
Let's collaborate for sustainability &
digitalization.

Open innovation Platform for sustainability.
Find the right opportuinty and grow up your
innovation ecosystem.

Sign in/up

Search an
opportunity

Do you want to be part of innovative a sustainable project? Search for your opportunity and make your contribution to for the sustainable growth of the economy and the planet.

Tech collaborations
Joint Ventures
Licensing
Subcontracting
Investment

Express interest
Established Slovak research institute and Slovak university...
created · Updated
Deadline: May 22, 2022
Received 0 expressions of interest

Summary

A team of inventors from an established Slovak scientific and research institute and an established Slovak university have developed a new pharmaceutically usable prodrug (cemtirestat disulfide) of a pharmacologically active compound (cemtirestat), which is an inhibitor of aldo-keto reductases, in particular aldose reductase.The novel prodrug can be used in the treatment of cancer that originates in chronic inflammation.The preferred cooperation type is license or financial agreement.

Description

Aldo-keto reductases are NAD(P)H-dependent oxidoreductases that are best characterized as glucose reducing agents. They are involved in the pathophysiology of diabetic complications. These enzymes also metabolize products of lipid peroxidation, thus contributing in certain circumstances to an inflammatory response.
Aldose reductase (AR, AKR1B1), besides being involved in diabetic complications through glucose reduction, effectively reduces aldehydes formed by lipid peroxidation, as well as their conjugates with glutathione, to the corresponding alcohols, which mediate inflammatory signals in the body.
It is very well documented that chronic inflammation is associated with cancer progression. Epidemiological studies suggest that more than 25% of all cases of cancer are closely related to chronic infection and chronic inflammation. Increased expression of aldo-keto reductases in tumors of lung, breast, prostate, cervix, testes and colon has been observed, and the role of aldo-keto reductases in the etiology of colorectal carcinoma has been confirmed.
Although a number of inhibitors of aldo-keto reductases have been extensively studied, none of them demonstrated sufficient efficiency in human clinical trials without adverse side effects. Thus, there is still a need for the development of new, efficient and safe inhibitors of aldo-keto reductases AKR1B1 and AKR1B10 as potential drugs for diabetic complications, inflammatory diseases and cancer.
3-mercapto-5H-1,2,4-triazino[5,6-b]indole-5-acetic acid (cemtirestat) has been designed and patented as a highly efficient and selective inhibitor of aldose reductase with antioxidant properties. Recently, the ability of cemtirestat to alleviate the symptoms of peripheral neuropathy in ZDF and STZ-induced diabetic rats has been described. Extremely low cytotoxicity of cemtirestat was demonstrated in vitro and, in addition, no significant changes were observed in Wistar rats in a 120-day toxicology test.
Although cemtirestat exhibits effective inhibition of aldo-keto reductases AKR1B1 and AKR1B10, it would be advantageous to improve its pharmacokinetic properties when administered orally and parenterally.
A team of inventors from an established Slovak scientific and research institute and an established Slovak university has managed to solve the above mentioned shortcomings by using a therapeutic strategy based on the administration of a prodrug (cemtirestat disulfide) of the active drug (cemtirestat). In this strategy (prodrug strategy), the release of the active drug occurs after chemical or metabolic activation of the inactive prodrug at the site of desired effect. This approach can significantly increase the availability of the drug at the site of action and reduce toxicity compared to direct drug administration.
Cemtirestat disulfide was synthesized and tested to obtain a prodrug of an effective inhibitor of aldose reductase. Given the key role of aldo-keto reductases AKR1B1 and AKR1B10 in the etiology of several types of cancer associated with chronic inflammation, it is assumed that the release of cemtirestat within tumor cells by reduction of its prodrug would increase the efficiency and especially the selectivity of the drug.

The institutes are looking for partner to cooperate with via license agreement or financial agreement. Details about preferred type of cooperation are more specified in the Partner Sought.

Advantages & innovations

Competitive advantage: • targeted distribution of effective drug into cancer cells, which can lead to higher efficiency and reduced side effects (compared to cemtirestat), • expected higher efficiency also with respect to the symmetry of cemtirestat disulfide and the provision of two molecules of effective AR inhibitor (cemtirestat) at once, • increased selectivity of action, thanks to the effective conversion of the prodrug to cemtirestat bound to the naturally increased reducing environment of tumors, • expected better absorbability of cemtirestat disulfide in the acidic environment of tumors (compared to cemtirestat), thanks to its higher lipophilicity.

Stage of development

Under development/lab tested

Partner sought

Type: The present invention can be used in the field of treatment of cancer originating in chronic inflammation, namely cancer of colon, lung, breast, liver, prostate, pancreas, endometrium and cervix. The present invention can be also used for the treatment of cancer as an adjuvant therapeutic in combination with clinically used chemotherapeutics that are substrates of aldo-keto reductases. Role: The institute and the university are looking for an industrial partner to cooperate with via license agreement or financial agreement.

Create an
opportunity

Show your project-opportunity to generate interest of potential partners or collaborators. Companies, freelancers, or research centers can meet in Nir-vana and become perfect team together!

Latest Opportunities

EIT Food Public Engagement Proof of Concepts Call for Proposals 2023,...

published
Deadline: Aug 15, 2024
Project full name: EIT Food Public Engagement Proof of Concepts Call for Proposals 2023, 2024, 2025
Project acronym: EIT Food PE PoC Call 2023, 2024, 2025
Grant agreement number: N/A
Total EU funding available: €360 000 per submission window (total for 3 rounds: €1 380 000)
By the date of the Calls’ launches a webpage will be activated at eitfood.eu/projects/public-engagement-proof-of-concepts-call

Join and create
your ecosystem

Meet and connect with experts from around the world. Generate your innovative ecosystem and interact with them thanks to the different functionalities of Nir-vana: exchange spaces, lists of opportunities, expression of interest

Dirk Kiefer
Cem Emre Memis
Build your project with
the best professionals
in the sector
Latest Opportunities

    EIT Food Public Engagement Proof of Concepts Call for Proposals 2023,...

    published
    Deadline: Aug 15, 2024
    Project full name: EIT Food Public Engagement Proof of Concepts Call for Proposals 2023, 2024, 2025
    Project acronym: EIT Food PE PoC Call 2023, 2024, 2025
    Grant agreement number: N/A
    Total EU funding available: €360 000 per submission window (total for 3 rounds: €1 380 000)
    By the date of the Calls’ launches a webpage will be activated at eitfood.eu/projects/public-engagement-proof-of-concepts-call
    Swedish SME in the hygiene sector produces washable re-usable absorbent underwear helping people with little leaks such as incontinence (urine escape due to bladder weakness) or other forms of leakage during periods or pregnancy. Compared to disposable products they are environmentally sustainable, less costly, providing a sense of normalisation and comfort for users. The SME is looking for sales agents, retailers, distributors interested in entering business collaboration agreements
    Company based in Sweden, is a pioneering force in digital cleaning training, specializing in e-learning for cleaners, supervisors, and clients. With a proven track record since 1994 and a recent foray into international markets, companyseeks strategic partnerships in Europe.
    Spanish company manufacturing vinegars, lemon juice, food dressings, balsamic creams and other related products in different types of containers and different formats and weights, is looking for wholesaler or distributor. Preferred channels: supermarkets, large distribution, convenience stores, hospitality services (hotels, restaurants and catering), gourmet shops and others.

The most relevant open & connected
network for sustainable business development.

Join now!

Sustainable
projects

Nir-vana wants to be the first open innovation platform focus on sustainability.

According to the EU Action Plan there is a huge need of change to a more sustainable future and to collaborate and assure to achieve the SDG.

Network
& experts

Nir-vana is the only platform integrating seamless "search and find" to the next stage of collaborating.

Get connected with experts and companies for partnering. Find trusted innovation advisors, certified by Enterprise Europe Network and build up your team of partners, companies and experts you need for your innovation.

Find public funding &
private investors

Discover potential funding opportunities for your innovation. On nir-vana you have access to national and EU funding programmes, public funding and private investors.

Get connected to consultants and advisors specialised on funding and grant preparation.